Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784858 | 0.93 | PDE4A (0.45) | CTSSTAS1R3TAS1R1 | |
| SCHEMBL484634 | 0.93 | PDE4A (0.45) | CTSSTAS1R3TAS1R1 | |
| SCHEMBL803446 | 0.89 | KMT2A (0.47) | HTTCTSSTAS1R3TAS1R1KMT2A | |
| SCHEMBL13131596 | 0.86 | KMT2A (0.44) | HTTCTSSTAS1R3TAS1R1KMT2A | |
| SCHEMBL30583628 | 0.85 | HTT (0.44) | HTTTAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL15074697 | 0.85 | LMNA (0.48) | TAS1R3TAS1R1KMT2AMEN1ALDH1A1 | |
| SCHEMBL2804784 | 0.85 | TRPV1 (0.50) | HTTCTSSTAS1R3TAS1R1KMT2A | |
| SCHEMBL397521 | 0.84 | NR1H2 (0.42) | HTTCTSSTAS1R3TAS1R1KMT2A | |
| SCHEMBL10256440 | 0.84 | LMNA (0.51) | HTTCTSSKMT2AMEN1ALDH1A1 | |
| SCHEMBL8225460 | 0.83 | PDE4A (0.45) | TAS1R3TAS1R1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | HTT 2709/4885CTSS 824/4885TAS1R3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.